NCT07053020 2026-03-04A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)M.D. Anderson Cancer CenterPhase 1/2 Not yet recruiting58 enrolled